Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: The precedent study

American Heart Journal

Volumn 144, Issue 6, 2002, Pages 1102-1108

  Burger, Andrew J ^a   Horton, Darlene P ^b   LeJemtel, Thierry ^c   Ghali, Jalal K ^d   Torre, Guillermo ^e   Dennish, George ^f   Koren, Michael ^g   Dinerman, Jay ^h   Silver, Marc ⁱ   Cheng, Mei L ^b   Elkayam, Uri ^j  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b SCIOS INC   (United States)

^c Albert Einstein Hospital   (United States)

^d Cardiac Centers of Louisiana   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f San Diego Cardiovascular Associates   (United States)

^g Jacksonville Center for Clinical Research   (United States)

^h Heart Center Research   (United States)

ⁱ ADVOCATE CHRIST MEDICAL CENTER   (United States)

^j LAC USC MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DOBUTAMINE; NESIRITIDE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HEART ARRHYTHMIA; HEART RATE; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE EXTRASYSTOLE; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0036915820     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2002.125620     Document Type: Article

References (21)

1. Dies F, Krell MJ, Whitlow P, et al. Intermittent dobutamine in ambulatory outpatients with chronic cardiac failure [abstract]. Circulation 1986;74:11-38.
2. David S, Zaks JM. Arrhythmias associated with intermittent outpatient dobutamine infusion. Angiology 1986;37:86-91.
3. La Vecchia L, Ometto R, Finocchi G, et al. Torsade de pointes ventricular tachycardia during low dose intermittent dobutamine treatment in a patient with dilated cardiomyopathy and congestive heart failure. Pacing Clin Electrophysiol 1999;22:397-9.
4. Krell MJ, Kline EM, Bates ER, et al. Intermittent, ambulatory dobutamine infusions in patients with severe congestive heart failure. Am Heart J 1986;112:787-91.
5. O'Connor CM, Gattis WA, Uretsky BF, et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: Insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J 1999;138:78-86.
6. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 1991;325:1468-75.
7. Yasue H, Yoshimura M, Sumida H, et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994;90:195-203.
8. Yoshimura M, Yasue H, Morita E, et al. Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation 1991;84:1581-8.
9. Mills RM, LeJemtel TH, Horton DP, et al. Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: A randomized, double-blind, placebo-controlled clinical trial. Natrecor study group. J Am Coll Cardiol 1999;34:155-62.
10. Colucci W, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med 2000;343:246-53.
11. Marcus LS, Hart D, Packer M, et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. Circulation 1996;94:3184-9.
12. Lainchbury JG, Richards MG, Nichollis EA, et al. Infusion or coinfusion of brain natriuretic peptide and/or adrenomedullin in human heart failure [abstract]. J Am Coll Cardiol 1998;31:156A.
13. Jensen KT, Hans E, Carstens J, et al. Renal effects of brain natriuretic peptide patients with congestive heart failure. Clinic Sci 1999;96:5-15.
14. Brunner-La Rocca HP, Kaye DM, Woods RL, et al. Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects. J Am Coll Cardiol 2001;37:1221-7.
15. Burger AJ, Elkayam U, Neibaur MT, et al. Comparison of the occurrence of ventricular arrhythmias in patients with acutely decompensated congestive heart failure receiving dobutamine versus nesiritide therapy. Am J Cardiol 2001;88:35-9.
16. Velebit V, Pondrid P, Lown B, et al. Aggravation and provocation of ventricular arrhythmias by antiarrhythmic drugs. Circulation 1982;65:886-94.
17. The CAPS Investigators. Cardiac arrhythmia pilot study. Am J Cardiol 1986;57:91-5.
18. Abraham WT, Lowes BD, Ferguson DA, et al. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Card Fail 1998;4:37-44.
19. Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival trial of antiarrhythmic therapy in congestive heart failure. N Engl J Med 1995;333:77-82.
20. Natrecor [package insert]. Sunnyvale, Calif: Scios; 2001.
21. VMAC Investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: A randomized controlled trial. JAMA 2002;287:1531-40.